First AD

Second AD

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

The Evolving Treatment Paradigm in Multiple Myeloma: Recent Updates

Peer Exchange

University of Wisconsin Carbone Cancer Center

Cancer Centers

Partner

Dana-Farber Cancer Institute

After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape. 

Multiple Myeloma: Unmet Needs and Future Directions in Care

What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy 

Induction Therapy Regimens for Transplant-Eligible NDMM

Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma 

Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma 

Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma

Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma

Patient Scenario: Treatment Options in MM at First Relapse 

Factors in Selecting Therapy at First Relapse in Multiple Myeloma 

Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy

Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment

Bispecifics in Multiple Myeloma: Dosing and Transition of Care

Combination Strategies With Bispecifics in Multiple Myeloma

Bispecifics in Multiple Myeloma: Adverse Event Management 

CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond